Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children’s Oncology Group

Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, Loken M, Brodersen LE, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2022 Jan;69(1):e29313. doi: 10.1002/pbc.29313. Epub 2021 Sep 2. PubMed PMID: 34472213; PubMed Central PMCID: PMC8919970.

The optimal number of chemotherapy courses for low-risk (LR) pediatric acute myeloid leukemia (AML) is not known. We compared relapse risk (RR), disease-free survival (DFS), and overall survival (OS), and the differential impact in LR subgroups for patients receiving four versus five chemotherapy courses. Cox (OS and DFS) and risk (RR) regressions were used to estimate hazard ratios (HR) to compare outcomes.